Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 422

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 422
---
 the Rewell segment increased by $61,536, or 111.3%, from $55,275 in the year ended June 30, 2023, to $116,811 in the year ended June 30, 2024. This growth is explained as follows: • volume effect: 29.5% of the increase ($18,153) is due to a 32.84% growth in the number of kits sold, reflecting expanded commercialization efforts and improved sales strategies; and

216 • price effect: 70.5% of the increase ($43,383) is due to a 78.49% rise in the average price per kit, which is quoted in U.S. dollars, driven by adjustments in pricing strategies and increased direct -to -consumersales. Overall, approximately 93.6% and 6.4% of total revenues were derived from the Heritas Diagnostics segment and the Rewell segment, respectively, in the year ended June 30, 2024, compared to 97.1% and 3.0%, respectively, in the year ended June 30, 2023. Cost of revenues Cost of revenues decreased by $45,705, or 2.4%, from $1,920,443 in the year ended June 30, 2023, to $1,874,738 in the year ended June 30, 2024. The reduction was mainly attributed to lower demand for diagnostic tests, leading to a proportional decrease in the utilization of reagents, sequencing consumables, and sample processing services. In addition to the reduced test volumes, several operational improvements contributed to lower reagent and consumable consumption: • operational efficiencies: sequencing workflow optimizations, including reducing machine runtime, led to a more efficient use of reagents and consumables; • improved sequencing efficiency: enhancements in sequencing protocols resulted in a reduced need for reagents per sample, optimizing their usage; and • streamlined sample processing: process improvements in sample preparation allowed for more efficient use of consumables such as extraction kits and buffers. These factors, combined with the lower test volumes, led to a decrease in the cost of revenues associated with genomic testing. Selling expenses Sales and marketing expenses decreased by $48,864, or 10.7%, from $451,207 in the year ended June 30, 2023, to $402,981 in the year ended June 30, 2024. This decrease was primarily attributed to a more efficient allocation of